The SiMoA assay has been used to demonstrate elevated blood levels of NfL in ALS, multiple sclerosis, oxaliplatin-induced peripheral neuropathy, and paclitaxel-induced neuropathy [19,20,23,41]. This evidence concerns the gene NEFL and multiple sclerosis.